<strong>Chiral Derivatives of Xanthones: Investigation of Enantioselectivity as Inhibitors of Cyclooxygenases (COX-1 and COX-2) and Binding Interaction with Human Serum Albumin</strong>

• DOI: 10.3390/ecmc-2-a023
• Publication Date: 2016-11-01T21:13:43Z
• Authors: Madalena Pinto; Carla Fernandes; Andreia Palmeira; Inês Ramos; Carlos Carneiro; Carlos Afonso; Maria Tiritan; Honorina Cidade; Paula Pinto; M. Lúcia Saraiva; Salette Reis
• Keywords: Human serum albumin

Searching for new enantiomerically pure chiral derivatives of xanthones (CDXs) with potential pharmacological properties has remained an area interest our group, namely those anti-inflammatory activity [1,2]. Herein, we describe in silico studies and vitro inhibitory assays different enantiomeric pairs CDXs. The evaluation the inhibition cyclooxygenases (COX-1 COX-2) activities was performed by using COX Inhibitor Screening Assay Kit. Docking simulations between small molecules (CDXs, known ligands decoys) enzyme targets were undertaken AutoDock Vina embedded PyRx – Virtual Tool software. All CDXs evaluated exhibited COX-1 COX-2 as predicted. Considering that (S)-(-)-enantiomer nonsteroidal drug Ketoprofen preferentially binds to albumin, resulting lower free plasma concentration than (R)-(+)-enantiomer [3], protein binding affinity also spectrofluorimetry. For some enantioselectivity observed. [1] Fernandes, C., et al. Bioorg Med Chem. 2014, 22(3), 1049-1062. [2] Eur. J. Med. 2012, 55, 1-11. [3] Evans, S. E. Trends Environmental Analytical Chemistry, 1(0), e34-e51. This research partially supported Structured Program R&D&I INNOVMAR –Innovation Sustainability Management Exploitation Marine Resources (reference NORTE-01-0145-FEDER-000035, Research Line NOVELMAR), funded Northern Regional Operational Programme (NORTE2020) through European Development Fund (ERDF) Foundation Science Technology (FCT) COMPETE under projects PTDC/MAR-BIO/4694/2014 (POCI-01-0145-FEDER-016790) COXANT–CESPU- 2016.